Skip to main content

Organon and CAF, Development Bank of Latin America, Launch First-of-Its-Kind Collaboration to Increase Sustainable Financing in Women’s Health

Agreement is part of a transformative model convening governments, global development banks and other multilateral agencies to use results-based financing to improve the lives of women

Today, Organon (NYSE:OGN), a global healthcare company focused on women’s health, and CAF, Development Bank of Latin America, signed a memorandum of understanding (MOU) to contribute to the United Nations Sustainable Development Goals through the design, structure and implementation of sustainable programs that promote and improve equity, health and autonomy of girls and women in Latin America and the Caribbean. Across the globe, tremendous gaps exist in women’s health that can potentially prevent women and thus economies from achieving their full potential. Sustainable financing can advance progress in women’s health by mobilizing capital towards initiatives that might not otherwise receive adequate support like increasing access to sexual and reproductive health education and healthcare services.

Sustainable financing is one potential solution to address constrained government budgets while catalyzing healthcarei and socioeconomic progress. Health-focused social impact investments – also known as results-based financing - can provide governments and investors with measurable and meaningful results, while reducing their risk. Yet as of 2020 health-related investments only represented 10% of the 190 billion global social bond issuances.ii

“At Organon, we believe that results-based financing can drive collective action to progressing women’s health goals,” said Kevin Ali, Organon CEO. We are proud of our first-of-its-kind collaboration with CAF, built specifically to positively affect the health of women – and ultimately a country’s economy and development.”

Organon’s collaboration with CAF will help prioritize and improve the health, equity, and autonomy of girls and women in Latin America and the Caribbean. It will help to ensure that women have the resources and support they need to lead healthy, fulfilling lives as well as contributing to economic development. One report revealed that if women were to participate in the economy identically to men, as much as $28 trillion – or 26% – could be added to the global GDP in 2025.iii

“This agreement with Organon will help us to join forces in order to break with the structural barriers that keep limiting the access of women to health, financial and non-financial services,” said Sergio Diaz-Granados, Executive President of CAF.

Organon has created a new, transformative model for convening governments and development global banks to improve the lives of women and girls and grow gross domestic product (GDP). By using data, Organon is helping governments understand the value sustainable finance can provide to their people and their economies through health-related investments. Programs are currently running in eight countries in different phases including Mexico, Colombia, Ecuador, Peru, Panama, as well as Thailand, Kenya, and South Africa.

About Organon

Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon offers more than 60 medicines and products in women’s health in addition to a growing biosimilars business and a large franchise of established medicines across a range of therapeutic areas. Organon’s existing products produce strong cash flows that support investments in innovation and future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey

For more information, visit and connect with us on LinkedIn, Instagram, Twitter and Facebook.

Cautionary Note Regarding Forward-Looking Statements

Some statements and disclosures in this news release are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as "may," “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will,” or words of similar meaning. These forward-looking statements are based on our current plans and expectations and are subject to a number of risks and uncertainties that could cause our plans and expectations, including actual results, to differ materially from the forward-looking statements.

Risks and uncertainties that may affect our future results include, but are not limited to, an inability to promote results-based financing in Latin America and the Caribbean through our contributions to the United Nations Sustainable Development Goals; an inability to negotiate a definitive agreement with CAF to supersede the MOU; changes in applicable laws or regulations; general economic factors, including recessionary pressures, interest rate and currency exchange rate fluctuations; general industry conditions and competition; global trends toward health care cost containment; financial instability of international economies and sovereign risk; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon’s filings with the Securities and Exchange Commission ("SEC"), including Organon’s Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent SEC filings, available at the SEC’s Internet site (


i Atun, R., Silva, S., & Knaul, F.M. (2017). Innovative financing instruments for global health 2002-15: a systematic analysis. The Lancet. Global Health, 5(7), e720-e726.

ii Asian Development Bank (2021). Promoting social bonds for impact investments in Asia.

iii Madgavkar, A., Ellingrud, K., Krishnan, M., (2016) The economic benefits of gender parity. Stanford Social Innovation Review.


Media Contacts:

Karissa Peer

(614) 314-8094

Kate Vossen

(732) 675-8448

Robert Valls

(+57) 3043578424

Investor Contacts:

Jennifer Halchak

(201) 275-2711

Alex Arzeno

(646) 430-2028

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.